✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Laboratorios Farmaceuticos ROVI SA

Common Name
Laboratorios Farmaceuticos ROVI
Country
Spain
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,197
Ticker
ROVI
Exchange
BOLSA DE MADRID
Description
Laboratorios Farmacéuticos Rovi SA is a Spanish biotechnology and pharmaceutical company specializing in the research, development, manufacturing, and marketing of small molecule and specialty biologi...

Laboratorios Farmaceuticos ROVI's GHG Emissions Data Preview

In 2024, Laboratorios Farmaceuticos ROVI completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Laboratorios Farmaceuticos ROVI has also provided a category-level breakdown for 6 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)202420232022
2021 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Total Scope 2
Market-Based
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Location-Based
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
a
0000000
Unspecified Calculation Method
Copy/Paste is a PRO feature.
0000000
Copy/Paste is a PRO feature.
0000000
Total Scope 3
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
a
Copy/Paste is a PRO feature.
a
0000000
Limited Data Preview
You are viewing a limited preview of Laboratorios Farmaceuticos ROVI’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2021, and revenue-based intensity metrics for each scope.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=ROVI&reporting_period=2024"

Verified Sources Behind Laboratorios Farmaceuticos ROVI’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Laboratorios Farmaceuticos ROVI’s data sources below and access millions more through our Disclosure Search.

a. Laboratorios Farmaceuticos ROVI's Sustainability Report 2024
b. Laboratorios Farmaceuticos ROVI's Integrated Report 2023

Insights into Laboratorios Farmaceuticos ROVI's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Laboratorios Farmaceuticos ROVI amounted to 18,808.98 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2023, the total operational greenhouse gas (GHG) emissions of Laboratorios Farmaceuticos ROVI increased by 13.11%, suggesting that the company faced challenges in reducing its emissions from its core operations.a

Laboratorios Farmaceuticos ROVI's Scope 1 Emissions Over Time

202120222023202402.5 k5 k7.5 k10 ktCO2e+21%+9%+16%
  • Total Scope 1
  • Year-over-Year Change

What are Laboratorios Farmaceuticos ROVI's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Laboratorios Farmaceuticos ROVI were 9,565.8 metric tons of CO₂ equivalent (tCO₂e).a

Has Laboratorios Farmaceuticos ROVI reduced its Scope 1 emissions over time?

Since 2021, Laboratorios Farmaceuticos ROVI's Scope 1 emissions have increased by 53.54%, reflecting a rising long-term trend in Scope 1 emissions over time.ab

Compared to the previous year (2023), Laboratorios Farmaceuticos ROVI's Scope 1 emissions increased by 16.08%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a

What are Laboratorios Farmaceuticos ROVI's Scope 2 emissions?

In 2024, Laboratorios Farmaceuticos ROVI reported Scope 2 greenhouse gas (GHG) emissions of 37.46 tCO₂e using the market-based method and 9,243.18 tCO₂e using the location-based method.a

Has Laboratorios Farmaceuticos ROVI reduced its Scope 2 emissions over time?

Compared to the previous year (2023), Laboratorios Farmaceuticos ROVI's Scope 2 emissions (Location-Based) rose by 10.18% in 2024, suggesting that the company faced challenges in reducing emissions from purchased electricity and energya

What methodology does Laboratorios Farmaceuticos ROVI use for Scope 2 reporting?

In 2024, Laboratorios Farmaceuticos ROVI reported its Scope 2 emissions using the market-based method and using the location-based method.a

Laboratorios Farmaceuticos ROVI's Scope 2 Emissions Over Time

202120222023202402.5 k5 k7.5 k10 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Laboratorios Farmaceuticos ROVI's Value Chain Emissions

In 2024, Laboratorios Farmaceuticos ROVI reported 12,099.63 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2024 disclosure of Laboratorios Farmaceuticos ROVI includes a breakdown across 6 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a

Laboratorios Farmaceuticos ROVI's Scope 3 Emissions Over Time

20222023202403.5 k7 k10.5 k14 ktCO2e-3%+17%
  • Total Scope 3
  • Year-over-Year Change

What are Laboratorios Farmaceuticos ROVI's Scope 3 emissions?

In 2024, Laboratorios Farmaceuticos ROVI reported total Scope 3 emissions of 12,099.63 metric tons of CO₂ equivalent (tCO₂e).a

Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a

Compared to the previous year (2023), Laboratorios Farmaceuticos ROVI's Scope 3 emissions increased by 16.93%, suggesting that the company faced challenges in reducing emissions across its value chain.a

What categories of Scope 3 emissions does Laboratorios Farmaceuticos ROVI disclose?

In 2024, Laboratorios Farmaceuticos ROVI reported emissions for 6 out of the 15 Scope 3 categories defined by the GHG Protocol.a

This partial disclosure allows for some insight into the company's indirect impacts.

What are the main sources of Laboratorios Farmaceuticos ROVI's Scope 3 emissions?

In 2024, the largest contributors to Laboratorios Farmaceuticos ROVI's Scope 3 emissions were:a

  • Purchased Goods and Services (Cat. 1): 5,186.28 tCO₂e (42.86%)
  • Waste Generated in Operations (Cat. 5): 3,352.12 tCO₂e (27.7%)
  • Employee Commuting (Cat. 7): 2,377.91 tCO₂e (19.65%)

Laboratorios Farmaceuticos ROVI's Scope 3 Emissions by Categories

Waste Generated inOperations (Cat. 5)(27.7%)Employee Commuting(Cat. 7)(19.7%)Purchased Goods andServices (Cat. 1)(42.9%)

Insights into Laboratorios Farmaceuticos ROVI’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Laboratorios Farmaceuticos ROVI reported Scope 1 greenhouse gas (GHG) emissions of 9,565.8 tCO₂e and total revenues of USD 795 millions. This translates into an emissions intensity of 12.04 tCO₂e per millions USD.a

Laboratorios Farmaceuticos ROVI's Scope 1 Emissions Intensity Compared to Peers

1001,0005,00050,000500,000Scope 1 Emissions (tCO2e)1002001,0005,00010,000Revenues (Millions of USD)PDVetoquinolYear: 2024Scope 1: 7,159 tCO2eRevenue: $M 561Scope 1 Intensity: 12.76 tCO2e/$MWalvax BiotechnologyYear: 2024Scope 1: 7,643 tCO2eRevenue: $M 387Scope 1 Intensity: 19.77 tCO2e/$MAlmirallYear: 2024Scope 1: 5,742 tCO2eRevenue: $M 1,026Scope 1 Intensity: 5.60 tCO2e/$MMega LifesciencesYear: 2023Scope 1: 1,809 tCO2eRevenue: $M 455Scope 1 Intensity: 3.97 tCO2e/$MLivzon Pharmaceutical GroupYear: 2024Scope 1: 194,441 tCO2eRevenue: $M 1,619Scope 1 Intensity: 120.13 tCO2e/$MAlembic PharmaceuticalsYear: 2025Scope 1: 80,278 tCO2eRevenue: $M 765Scope 1 Intensity: 104.88 tCO2e/$MAjanta PharmaYear: 2025Scope 1: 6,392 tCO2eRevenue: $M 537Scope 1 Intensity: 11.90 tCO2e/$MFagronYear: 2023Scope 1: 4,218 tCO2eRevenue: $M 844Scope 1 Intensity: 4.99 tCO2e/$MJoincareYear: 2024Scope 1: 197,854 tCO2eRevenue: $M 2,140Scope 1 Intensity: 92.45 tCO2e/$MGrape King BioYear: 2024Scope 1: 6,559 tCO2eRevenue: $M 341Scope 1 Intensity: 19.25 tCO2e/$MWockhardtYear: 2025Scope 1: 11,404 tCO2eRevenue: $M 341Scope 1 Intensity: 33.43 tCO2e/$MPPPorton Pharma SolutionsYear: 2024Scope 1: 18,865 tCO2eRevenue: $M 413Scope 1 Intensity: 45.71 tCO2e/$MHUTCHMED (China)Year: 2024Scope 1: 3,083 tCO2eRevenue: $M 4,926Scope 1 Intensity: 0.63 tCO2e/$MBioKangtaiYear: 2023Scope 1: 15,952 tCO2eRevenue: $M 489Scope 1 Intensity: 32.60 tCO2e/$MZhejiang Jiuzhou PharmaceuticalYear: 2023Scope 1: 48,815 tCO2eRevenue: $M 777Scope 1 Intensity: 62.81 tCO2e/$MAbbott IndiaYear: 2025Scope 1: 232 tCO2eRevenue: $M 750Scope 1 Intensity: 0.31 tCO2e/$MYuhanYear: 2024Scope 1: 7,059 tCO2eRevenue: $M 1,409Scope 1 Intensity: 5.01 tCO2e/$MGedeon RichterYear: 2024Scope 1: 45,632 tCO2eRevenue: $M 2,171Scope 1 Intensity: 21.02 tCO2e/$MGlenmark PharmaceuticalsYear: 2025Scope 1: 34,547 tCO2eRevenue: $M 1,539Scope 1 Intensity: 22.45 tCO2e/$MDDDong-E-E-JiaoYear: 2023Scope 1: 15,659 tCO2eRevenue: $M 663Scope 1 Intensity: 23.60 tCO2e/$MAlkem LaboratoriesYear: 2025Scope 1: 33,018 tCO2eRevenue: $M 1,499Scope 1 Intensity: 22.03 tCO2e/$MFaes FarmaYear: 2024Scope 1: 5,016 tCO2eRevenue: $M 514Scope 1 Intensity: 9.76 tCO2e/$MPiramal PharmaYear: 2025Scope 1: 61,351 tCO2eRevenue: $M 1,061Scope 1 Intensity: 57.85 tCO2e/$MIPCA LaboratoriesYear: 2025Scope 1: 169,992 tCO2eRevenue: $M 1,036Scope 1 Intensity: 164.03 tCO2e/$MLaboratorios Farmaceuticos ROVIYear: 2024Scope 1: 9,566 tCO2eRevenue: $M 795Scope 1 Intensity: 12.04 tCO2e/$M

How does Laboratorios Farmaceuticos ROVI's GHG emissions intensity compare to its peers?

In 2024, Laboratorios Farmaceuticos ROVI reported a Scope 1 emissions intensity of 12.04 tCO₂e per millions USD. Compared to the peer group median of 21.53, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Laboratorios Farmaceuticos ROVI rank on GHG emissions intensity within its industry?

In 2024, Laboratorios Farmaceuticos ROVI ranked 9 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

Laboratorios Farmaceuticos ROVI is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Insights into Laboratorios Farmaceuticos ROVI's Total Carbon Footprint

In 2024, Laboratorios Farmaceuticos ROVI reported a total carbon footprint of 30,908.61 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 14.57% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.a

The largest contributor to Laboratorios Farmaceuticos ROVI's total carbon footprint was Scope 3 emissions, accounting for 39.15% of the company's total carbon footprint, followed by Scope 1 emissions at 30.95%.a

Want Full Access to Laboratorios Farmaceuticos ROVI's GHG Emissions Dataset?
Start 30-Day Free Trial